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Hypertension and diabetes mellitus are considered to be two major atherosclerotic risk factors for coronary artery disease (CAD).
A stress-induced protein identiﬁed to be dermcidin isoform 2 of Mr. 11kDa from blood plasma of hypertensive persons when
injected (0.1μM) in rabbits increased the systolic pressure by 77% and diastolic pressure by 45% over the controls within 2h.
Ingestionofacetylsalicylicacid(150mg/70kg)bythesesubjectsreducedsystolic(130mmHg)anddiastolicpressures(80mmHg)
with reduction of plasma dermcidin level to normal ranges (9nM). The protein was found to be a potent activator of platelet
cyclooxygenase and inhibited insulin synthesis. Aspirin was found to reduce hypertension by reduction of plasma dermcidin level,
neutralizedtheeﬀectofcyclooxygenase,andrestoredthepancreaticinsulinsynthesisthroughNOsynthesis.Theseresultsindicated
that dermcidin could be a novel atherosclerotic risk factor for its hypertensive and diabetogenic eﬀects.
1.Introduction
Acute ischemic heart disease (AIHD), a life-threatening con-
dition, has been reported to be developed as a result of for-
mation of thrombus due to the aggregation of platelets on
the site of atherosclerotic plaque rupture on the wall of
coronary artery [1]. The aggregation of platelets by itself
is a life-saving process in the blood coagulation through
the formation of prothrombinase complex on the activated
platelet surface [2]. In contrast, extensive platelet aggre-
gation on the site of the atherosclerotic plaque rupture
resulted in the precipitation of AIHD [1]. And, as such, the
atherosclerosis plays a critically important role in the genesis
of prothrombotic condition leading to AIHD [3]. Indeed,
in the absence of atherosclerosis, the platelet aggregation in
many cases could be considered as a beneﬁcial physiologic
event. Diabetes mellitus (both type I and type II) and
hypertension are considered to be the two major risk factors
forprothromboticconditionleadingtoAIHD.Dyslipidemia,
hyperhomocysteinemia, dysregulation of blood coagulation
and ﬁbrinolysis and inﬂammatory reaction are also reported
to be atherosclerotic risk factors albeit lesser importance [4].
Although stress has been reported to instigate both
diabetes mellitus [5] and hypertension [6], the interaction
between these two risk factors remains obscure and specu-
lative [7] except that hypertension is found to be associated
with insulin resistance and dyslipidemia [8].
While the mechanism of insulin-induced hypertension
remains obscure, insulin resistance itself is known to cause
diabetic dyslipidemia. On the other hand, insulin itself has
been reported to be a potent ﬁbrinolytic agent both in vivo
and in vitro through the formation of NO [9], and diabetes
mellitus itself as a consequence may impair ﬁbrinolysis [10].
In other words, many of the prothrombotic risk factors can
arise due to impairment of the insulin eﬀects [11].
Astress-inducedoxidativeprotein,identiﬁedtobederm-
cidin isoform 2 (dermcidin) that has been reported to ap-
pear in the circulation in AIHD, is also found to be a po-
tent platelet aggregating agent [12]. In a follow-up study,
it was found that dermcidin was a potent inhibitor of2 Thrombosis
insulin-induced NO synthesis in endothelial cells. As NO
is reported to be a global vasodilatory agent [13] and the
endothelial NO synthesis would play a critically important
role in the control of hypertension [13], experiments were
carried out to determine the role of dermcidin on the devel-
opment of hypertension in animal model and in subjects
suﬀering from systemic hypertension.
We report herein that the oxidative stress protein which
was found to be a powerful inducer of platelet aggregation
[12] not only inhibited insulin synthesis in the pancreatic β
cells but also was a potent inhibitor of the hormone synthesis
in the hepatocytes in the liver which has been reported
to be an important source of the extrapancreatic hormone
synthesis [14].
We also report that aspirin was found to inhibit the
proatherosclerotic activities of dermcidin by restoring the
synthesis of insulin as well as by normalizing the elevated
blood pressure through the reduction of plasma level of the
oxidativeproteinlevelinducedbythesystemicstimulationof
NO synthesis.
2. Methods
2.1. Ethical Clearance. The protocol was approved by the
Internal Review Board, Sinha Institute of Medical Science
and Technology, Kolkata. All participants were asked to sign
informed consent form. This study also used adult New
Zealand rabbits. Appropriate permission was also obtained
from the IRB.
2.2. Chemicals. Goat anti-rabbit immunoglobulin G-
alkaline phosphatase was obtained from Sigma Chemical
Co. Aspirin was obtained from Medica Zydus Healthcare.
Maxisorp plates were from Nunc, Roskilde, Denmark. All
other chemicals were of analytical grade.
2.3. Selection of Hypertensive Persons. All participating vol-
unteers in the study came to Kolkata Medical College and
Hospital, Kolkata as “outdoor” patients. Equal number of
male and female volunteers with hypertension (n = 74, in
each group) participated in the study. These hypertensive
patients came to the hospital with minor ailments often with
clinically undeﬁned malaise. They were between the ages
of 25 and 65 years. At presentation, none of the patients
were aware of the fact that they had elevated blood pressures
(BPs), and, as such, they never received any treatment for
the condition. Any of these subjects who had systolic BP
≥ 140mm of Hg and diastolic BP ≥ 90mm of Hg was
considered to be hypertensive [15] and was included in
the study without any regard to the underlying etiologic
mechanism involved in the development of the condition.
The BPs were measured by sphygmomanometer.
2.3.1. Exclusion Criteria for Hypertensive Patients. Patients
with history of diabetes mellitus or with any life-threatening
infection or cardiovascular/cerebrovascular conditions were
excluded from the study. Care was also taken to exclude
patients who were hospitalized for any condition within the
last two months as well as the persons who were taking any
medication including antihypertensive drug or aspirin.
2.4. Selection of Acute Myocardial Infarction (AMI) Patients.
All patients (n = 29) between ages of 49 and 61 (median
age 54 years) were admitted to the Intensive Care Unit of the
Calcutta Medical College and Hospital, Kolkata.
These patients met the following criteria of AMI: they
had chest pain characteristic of myocardial ischemia for
30mins or more and the electrocardiogram (ECG) showed
ST segment elevation of at least two leads in the ECG
reﬂectingasinglemyocardialregion.Theconﬁrmationofthe
conditionwasdeterminedbytheelevatedcreatinekinaseand
creatine kinase-MB isoenzyme assay in the blood plasma.
The sampling of blood was made within 6h of the onset
of the anginal attack before any therapy for the condition
was initiated. Only those AMI patients who refused to ingest
aspirin due to personal/religious beliefs served as “controls”
when necessary.
2.4.1. Exclusion Criteria. (1) Patients with the history of
diabetes mellitus, (2) showing the presence of bundle branch
b l o c ko rl e f tv e n t r i c u l a rh y p e r t r o p h yi nt h eE C G( 3 )o r
suﬀering from any severe infection, (4) took aspirin at least
within 2 weeks, (5) hospitalized forany condition within two
months, and (6) took any cardiac medication including any
antihypertensivedrugwithinlast21dayswereexcludedfrom
the study.
2.5. Selection of Normal Subjects. Age- and sex-matched nor-
m a lv o l u n t e e r s( n = 74) also participated in the study. Se-
lected volunteers had normal kidney functions as deter-
mined by their plasma creatinine (<1mg/dL) and urea (6–
17mg/dL) levels. The urinary excretion of protein in the
normal participants was <125mg/day. The HDL and LDL
levels were also within normal limits. No female volunteers
had ever taken any contraceptive medication.
2.6.CollectionofBlood. Bloodsamples(20–25mL),obtained
from the participants by venipuncture by using 19-gauge
siliconized needles, were collected in plastic vials and anti-
coagulated by gently mixing 9vol of the blood with 1vol
of 0.13mM sodium citrate [16]. The cell-free plasma (CFP)
was prepared by centrifuging the blood sample from the
participants at 30,000g for 30min at 0◦C.
2.7.IdentiﬁcationofDermcidinintheCell-FreePlasmaSample
fromHypertensivePatients. Asmentionedbefore,anewplas-
ma protein of Mr 11kDa was found to be present in the CFP
of the AMI patients [12]. As described under Section 3,t o
determine whether this protein might also be present in the
plasma of hypertensive persons, when the CFP from hyper-
tensive plasma was subjected to SDS- polyacrylamide gel
electrophoresis [17], a novel protein band of Mr. 11kDa was
found to be present in the gel in the case of hypertensive CFP
compared to that in the CFP from normal volunteers. This
protein band of Mr 11kDa was next excised from the gel,
triturated in 0.9% NaCl, and clariﬁed by centrifugation. TheThrombosis 3
clariﬁedsamplewasreelectrophoresedonpolyacrylamidegel
in the absence of SDS. The staining of the gel demonstrated
the presence of a single band. The staining of an identical gel
with AgNO3 [18] failed to show the presence of any other
band in the gel. The 11kDa band in an identical gel, not
stained with AgNO3 was excised out of the gel, triturated
in 0.9% NaCl, and dialyzed overnight at 4◦C against 0.9%
NaCl. The ﬁnal gel slices were washed twice with 50%
high-performance liquid chromatography grade acetonitrile
in water for 2-3min with gentle shaking and discarding
the supernatant after each wash. The amino acid sequence
of the protein sample thus prepared was determined by
Mass Spectrometry and Proteomic Resource Core, Harvard
University using microcapillary reverse-phase HPLC nano-
electrospray tandem mass spectrometry (μLC/MS/MS) on a
Thermo LTQ-Orbitrap mass spectrometer. The protein was
identiﬁed to be dermcidin isoform 2, an oxidative stress
protein, composed of 105 amino acids, that was previously
found to be present in the plasma of AMI patients [12].
2.8. Preparation of Dermcidin. Dermcidin used for its bio-
logical activity was prepared by sequential polyacrylamide
gel electrophoresis in the presence and absence of SDS
as described above. The isolated protein preparations was
pooled and concentrated by using polyethylene glycol as
described [19]. Before use, the concentrated preparation was
dialyzed overnight at 4◦C against 0.9% NaCl.
2.9. Measurement of BP in Animal Model. Normal adult New
Zealand white rabbits of either gender were used for the
study. To ensure that the animals were disease free, they were
subjected to a thorough checkup by a licensed veterinarian.
A mercury sphygmomanometer was used to record the BPs
of the animals [20].
2.10. Assay of NO Synthesis. The synthesis of NO was deter-
mined by methemoglobin method [21]a sd e s c r i b e db e f o r e .
The validity of the assay was conﬁrmed by an independent
chemiluminescence method [22].
2.11. Enzyme-Linked Immunosorbent Assay (ELISA) of Derm-
cidin. Polyclonalantibodyagainstpuredermcidinwasraised
in adult New Zealand rabbit by intradermal injection of
dermcidin emulsiﬁed with Freund’s adjuvant as described
[12].
The feasibility of the determination of dermcidin by
ELISA [23] was tested by immunoblot technique [24]. The
analytical precision of the assay for dermcidin by ELISA
as determined by “recovery” experiments was found to be
>90%.
2.12. ELISA of Insulin. Insulin synthesized in the pancreatic
islets of Langerhans was quantitated by ELISA as described
before [12, 23].
2.13. Oral Administration of Aspirin. In some phase of this
study, the selected subjects were asked to take an adequate
meal consisting of carbohydrate rich food like bread as well
as foods rich in protein like meat (90gm/70kg body weight),
milk, and cheese and then swallow a 150mg aspirin tablet
with water.
2.14. The Preparation of Platelet-Rich Plasma and the Deter-
mination of Platelet Aggregation. The platelet-rich plasma
(PRP)waspreparedfromtheanticoagulatedbloodbycentri-
fuging the sample at 200g as described [16]. The aggregation
of platelets of normal volunteers was carried out in a platelet
aggregometer (SEAC Clot 2S) using ADP as the aggregating
agonist as described before [16]. The aggregation of platelets
in PRP of these normal volunteers was also studied using
diﬀerent concentrations of dermcidin as an aggregating
agent in a similar way as in the case of ADP.
2.15. Determination of Thromboxane A2 Synthesis in Platelets.
The production of thromboxane A2 was determined by ra-
dioimmunoassay of thromboxane B2 [16]. After the aggre-
gation of platelet was completed (5min) at 37◦C, the for-
mation of thromboxane B2 was assayed to determine the
synthesis of thromboxane A2.
2.16. The Preparation of Goat Carotid Artery Endothelial Cell
Homogenate. Endothelialcellswerepreparedfromthecarot-
id artery of the freshly slaughtered goat as described before
[25]. The endothelial cell suspension in Tyrod’s buﬀer pH
7.4 was disrupted by repeated freezing and thawing the cell
suspension (20mg/mL) in liquid N2 [25]. The disrupted cell
mass was centrifuged at 60,000g for 30min at 0◦C. The
supernatantwasusedasthesourceofendothelialnitricoxide
synthase (eNOS).
2.17. Lineweaver-Burk Plot of Insulin-Activated eNOS in the
Endothelial Cell Homogenate in the Presence or Absence of
Dermcidin. The reaction mixture contained diﬀerent con-
centrations of l-arginine in the presence of 2mM CaCl2 with
100μunits of insulin/mL and in the presence or absence of
0.1μM dermcidin in Tyrod’s buﬀer pH 7.4 in a total volume
of 1.0mL. After 20min of incubation at 37◦Cu n d e rN 2,
(during the steady state of formation of NO (1–30min)) the
product NO was determined as described before [21].
2.18. Preparation of the Islets of Langerhans from the Mice
Pancreas and the Determination of the Eﬀect of Dermcidin on
the Glucose-Induced Synthesis of Insulin in the Pancreatic Islets
of Langerhans. In some phases of the study, it was necessary
to determine the glucose-induced synthesis of insulin using
the islets of Langerhans. The islets of Langerhans were pre-
pared and suspended in Krebs’ bicarbonate buﬀer (pH 7.4)
as described [12] and were incubated with or without 0.02M
glucose in the presence and absence of 0.1μM dermcidin
at 37◦C for 0–30min, and the synthesis of insulin was
determined by in vitro translation of the mRNA [26]. Insulin
produced was determined by ELISA as described above.
2.19. Statistical Analysis. The signiﬁcance of the results
obtained was analyzed by Student’s t-test. Signiﬁcance P<
0.0001isconsideredtobesigniﬁcant.Correlationcoeﬃcient,4 Thrombosis
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Figure 1: Sodium dodecyl sulfate polyacrylamide gel electrophore-
sis of the cell-free plasma from hypertensive and normotensive sub-
jects. Cell-free plasma (CFP) was prepared from the blood samples
of hypertensive and normotensive subjects and electrophorosed in
SDS-polyacrylamide. The protein band was stained by Coomassie
brilliant blue as described in Section 2. The arrow indicates the
position of 11kDa protein band. The ﬁgure represents the typical
gelelectrophoresisoftheCFPfromatleast10diﬀerenthypertensive
and normotensive subjects.
Pearsonscore“r”,issuchthat−1≤ r ≤+1isconsideredtobe
acceptable. The (+) and (–) signs are used for positive linear
correlations and negative linear correlations, respectively.
Whereappropriate,thesigniﬁcanceoftheresultswasveriﬁed
by nonparametric Mann Whitney U test.
3. Results
3.1. Appearance of Dermcidin in the Circulation of Hyperten-
sive Patients. As mentioned earlier, theremight belikelihood
that the stress-induced protein(s) might play a role in the
genesis of systemic hypertension. To verify this possibility
of the presence of any novel protein(s) in the circulation of
hypertensive patients which may result in the elevation of
the BPs, the plasma sample of the hypertensive patients was
electrophorosed on SDS-polyacrylamide gel. The staining of
thegelwithCoomassieBrilliantBluerevealedthepresenceof
a new protein band of Mr 11kDa in the plasma of hyperten-
sive patients compared to that in normal controls (Figure 1).
As described in Section 2, repeated gel electrophoresis of
the excised protein band from the hypertensive subjects in
the absence of SDS was analyzed to determine the amino
acid sequence which demonstrated that the novel protein
was comprised of 105 amino acids. The protein database
matching identiﬁed the protein to be dermcidin isoform 2
(hereafter referred to as dermcidin only), which has been
reported before to be an oxidative stress protein [12].
3.2. Eﬀect of Dermcidin on the Blood Pressure and NO Levels
in the Animal Model. Experiments were carried out to deter-
mine the eﬀect of dermcidin on the systemic blood pressure
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Figure 2: The eﬀect of injection of dermcidin to the rabbits on
the systolic and diastolic pressures and on the plasma NO level at
diﬀerent times after the injection of the protein. The electrophoret-
icallypuriﬁeddermcidinwasinjectedtothecirculationof“normal”
rabbits (1.0nmol/kg body weight). Both systolic and diastolic
pressures and the plasma NO levels were determined at diﬀerent
time after the administration of the oxidative stress protein. The
results shown are mean ± SD of six diﬀerent experiments 3 times
each using 6 diﬀerent rabbits.
levels, if any, in animal model using rabbit. The oxidative
stress protein was injected (1.0nmol/kg body weight) in the
ear vein of the test animals, and the blood pressures were
recorded at diﬀerent time intervals. It was found that the
venous injection of dermcidin (1.0nmol/kg body weight)
in the animal resulted in the elevation of basal systolic
pressure of 155 ±4.78mm of Hg to 200 ±10mm of Hg with
simultaneous increase of diastolic pressure of 57.5±8.66mm
Hgto125±5.77mmHgafter2hoftheinjection(P<0.0001,
n = 5) (Figure 2). However, it was also noted that after 2h
there was a gradual reduction in the level of the elevated
BP in this animal model reaching to ≈“normal” ranges (i.e.,
the BPs at the pretreatment level) of 147 ± 5.77mm Hg
(systolic) and 69.15 ± 10mm Hg (diastolic) at 4h. These
results suggested that the increase of dermcidin (1.0nmol/kg
bodyweight)intheanimalmodelledtoanacuteelevationof
BPswhichpersistedfor2h,andthereaftertherewasagradual
normalization of the elevated BPs in the test animal.
It has been reported before that increase in BP levels
was associated with the reduction of systemic nitric oxide
(NO) level [27]. Studies were carried out to determine the
eﬀect of dermcidin on the plasma NO level in the test
animals. When dermcidin (≈1μM) was injected in the test
animals, and blood samples were collected from the ear
vein to determine NO level in the plasma at diﬀerent time
intervals, it was found that the basal NO level prior to
dermcidin injection, which was 4.8 ± 0.127nmol/mL, was
reduced to 0.447±0.017nmol/mL (P<0.0001, n = 5) at 2h
(Figure 2). However, after 2h, there was a gradual retrieval
of the systemic NO level which reached to ≈“normal” ranges
(3.5nmol) at 4h. The plasma dermcidin level in the rabbits
that was found to increase to 98.48 ± 10.8nM after theThrombosis 5
Table 1: Correlation between plasma dermcidin level and systolic and diastolic pressures in normotensive and hypertensive subjects.
Normotensive subjects Hypertensive subjects
Parameters Dermcidin
(pmol/mL)
Systolic blood
pressure
(mm of Hg)
Diastolic
blood
pressure
(mm of Hg)
NO (nmol/h) Dermcidin
(pmol/mL)
Systolic blood
pressure
(mm of Hg)
Diastolic
blood
pressure
(mm of Hg)
NO (nmol/h)
Range 0–24 115–130 75–85 4.0 ±1.4 43.1–175 150–180 85–110 0.4 ±0.19
Median 5 125 80 98 160 90
“Pearson r”(c o rr elatio nc oe ﬃcient) =+0.922and+0.844betweendermcidinlevelandsystolicanddiastolicpressures, respectively,innormotensivesubjects.
“Pearson r”( c o r r e l a t i o nc o e ﬃcient) = + 0.924 and + 0.909 between dermcidin level and systolic and diastolic pressures, respectively, in hypertensive subjects.
The signiﬁcance (P value) was P<0.0001 between dermcidin levels, systolic and diastolic pressures in the normotensive and hypertensive subjects as
determined by the Mann Whitney U test with the medians signiﬁcantly diﬀerent.
Blood samples were collected from both normotensive and hypertensive subjects (n = 74 in each group) by venipuncture as described in Section 2.T h e
plasma dermcidin level was determined by ELISA by using electrophoretically puriﬁed dermcidin as described. The blood pressures were determined by
sphygmomanometer at presentation.
injection of the protein at 2h was simultaneously found to
decrease to 33.78 ±7.44nM at 4h (P<0.0001).
In the control experiment, equal numbers of animals
were administered with equal volume of 0.9% NaCl solution.
In contrast to dermcidin, the vehicles alone had no eﬀect
either on the pressure or NO.
3.3. Plasma Dermcidin Level in Hypertensive and Normoten-
sive Subjects. As the above results indicated that dermcidin
mightbeinvolvedintheincreaseofsystemicbloodpressures,
the plasma levels of the oxidative stress protein in the
circulation of hypertensive subjects (n = 74) as well as in
equal number of normotensive subjects were compared to
determine the correlation between the BPs level and plasma
dermcidinlevel.Itwasfoundthattheplasmadermcidinlevel
in hypertensive subjects was 98pmol/mL (median ranging
between 43.1 to 175pmol/mL) which was signiﬁcantly
higher compared to normotensive subjects [5pmol/mL
(median ranging between 0–24pmol/mL)]. Mann Whitney
U test between the dermcidin levels in these two groups
showed that the P (signiﬁcance) value was < 0.0001. The
coeﬃcient of correlation “r” between the plasma dermcidin
and BP levels was determined to be highly and positively
correlated (Table 1).
3.4. The Eﬀect of Reduction of Plasma Dermcidin Level on
the Systemic Blood Pressure in Hypertensive Subjects. It has
been reported before that the oral ingestion of acetyl salicylic
acid (aspirin) resulted in the reduction of dermcidin level
through the increase of systemic NO level [12]. As the
results described above indicated that the increase of plasma
dermcidin level could lead to the increase of systemic BPs
that was associated with the reduction of plasma NO level,
studies were conducted to determine whether the reduction
of dermcidin level could actually result in the reduction of
systemicBPsinhypertensivesubjects.Astheoralingestionof
aspirin has been reported to decrease the plasma dermcidin
level [12], the participating hypertensive subjects (n = 74)
were asked to ingest 150mg aspirin as described in Section 2.
It was found that, 3h after the oral ingestion of aspirin,
the plasma dermcidin level in these hypertensive subjects
AB
Dermcidin
Figure 3:SDSgelelectrophoresisofplasmaofhypertensivepatients
before and after the ingestion of aspirin. The plasma from the
hypertensive patients was subjected to SDS polyacrylamide gel
electrophoresis before (Lane A) and after (Lane B) the ingestion of
aspirin. As described in Section 2, patients were asked to swallow
150mg aspirin. After 3h of the ingestion of the compound, CFP
waspreparedandSDSgelelectrophoresiswasrunandsubsequently
stained with Coomassie Brilliant Blue. Please note that the intensity
of the 11kDa protein band was less dense (Lane B) compared to
before the ingestion of aspirin (Lane A). The ﬁgure shown here is a
typical representative of at least 10 more identical experiments.
decreased from 98nM (median, ranging from 43.1nM to
175nM) to 19.1nM (median, ranging from 2.9nM to
51nM) with decrease of both systolic (160 to 130mm of
Hg (Median)) and diastolic pressures (90 to 80mm of Hg
(Median)) (Table 2). SDS polyacrylamide gel electrophoresis
of the plasma from the hypertensive patients who had
ingested aspirin showed a markedly less intense band of
dermcidin (Mr 11kDa) when compared to patients who did
not undergo aspirin treatment (Figure 3).6 Thrombosis
Table 2: Eﬀect of oral ingestion of aspirin on the blood pressures and on the dermcidin levels in hypertensive subjects.
Hypertensive subjects
Before aspirin ingestion After aspirin ingestion
Parameters Dermcidin
(pmol/mL)
Systolic blood
pressure
(mm of Hg)
Diastolic
blood
pressure
(mm of Hg)
NO (nmol/h) Dermcidin
(pmol/mL)
Systolic blood
pressure
(mm of Hg)
Diastolic
blood
pressure
(mm of Hg)
NO (nmol/h)
Range 43.1–175 150–180 85–110 0.4 ±0.19 2.9–51 115–140 75–85 1.9 ±0.5
Median 98 160 90 19.1 130 80
“Pearsonr”(correlationcoeﬃcient)=+0.924and=+0.909betweendermcidinlevelandsystolicanddiastolicpressures,respectively,beforeaspiriningestion.
“Pearson r”( c o r r e l a t i o nc o e ﬃcient) = + 0.689 and + 0.846 between dermcidin level and systolic and diastolic pressures, respectively, after the ingestion of
aspirin.
The signiﬁcance (P value) was P<0.005 between dermcidin levels, systolic and diastolic pressures in hypertensive subjects before and after aspirin ingestion
as determined by the Mann Whitney U test with the medians signiﬁcantly diﬀerent.
Hypertensive subjects (n = 74) were asked to swallow one 150mg of aspirin with water after having a meal as described in Section 2. Both the blood pressures
and dermcidin levels were determined before the ingestion of aspirin and 3h after the ingestion of the compound.
3.5. ADP and Dermcidin-Induced Platelet Aggregation and
the Stimulation of Thromboxane A2 Synthesis. Since hyper-
tension has been reported to be a major risk factor for
coronary artery disease, it was thought that the occurrence
of this oxidative stress protein in hypertensive plasma could
ultimately lead to coronary artery disease through increased
platelet aggregation leading to thrombosis [12]. Experiments
were carried out to determine whether the electrophoreti-
cally puriﬁed oxidative stress protein from the hypertensive
plasmabySDSpolyacrylamidegelelectrophoresiscouldhave
any eﬀect on the aggregation of platelets. The aggregation of
platelets was studied by adding diﬀerent concentrations of
the puriﬁed dermcidin to PRP as described in Section 2.T h e
dermcidin-induced platelet aggregation was compared to
thatinducedbyADP,whichisreportedtobethemostimpor-
tant platelet aggregating agent in the genesis of the coronary
artery disease in man due to the aggregation of platelets
in the coronary artery [2]. It was found that dermcidin
(0.1μM), on mol/mol basis, was ≈40-fold stronger platelet-
aggregating agent compared to ADP (4.0μM) (P<0.0001;
n = 10) (Figure 4). Furthermore, like ADP, the oxidative
stress protein was found to be a potent stimulator of
thromboxane A2 synthesis in platelets through the activation
of cyclooxygenase [16]. It was found that the treatment
of normal PRP with 4μM ADP resulted in the synthesis
of 21.3 ± 3.6pmol of thromboxane A2/108 platelets after
5min of incubation at 37◦C. The treatment of the same PRP
with 0.1μM dermcidin resulted in the production of 29.2 ±
3.6pmol thromboxane A2/108 platelets under otherwise
identical conditions (P<0.0001; n = 10). Addition of
dermcidin together with ADP showed “superaggregation of
platelets” in the presence of 0.1μM dermcidin and 4.0μM
ADP (Figure 4) that resulted in the stimulated production of
31.5±5.22pmol thromboxane A2/108 platelets. These results
indicated that dermcidin had an additive eﬀect on the ADP-
induced platelet aggregation with concomitant increase of
thromboxane A2 synthesis. On the other hand, incubation
of the platelet-rich plasma with 80μM aspirin, a well-known
inhibitor of platelet cyclooxygenase [28], and ADP-induced
platelet aggregation [29] was also capable of inhibiting the
aggregation induced by dermcidin (Figure 4).
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Figure 4: Aggregation of platelets by ADP and dermcidin and
the aggregation of platelets in the presence of both ADP and
dermcidin added to PRP. Platelet-rich plasma was prepared from
the blood of normal volunteers, and the aggregation of platelet
was determined by treating the PRP with either ADP (4μM) or
dermcidin (0.1μM) or with both ADP and dermcidin. The curve
A: aggregation of platelets when both ADP and dermcidin were
addedtothePRP.CurveB:dermcidin-inducedplateletaggregation.
Curve C: ADP-induced platelet aggregation. Curve D: aspirin-
(80μM) induced inhibition of platelet aggregation induced by
dermcidin. The ﬁgure represents a typical platelet aggregation in
thepresenceofADP,dermcidin,orbothADPanddermcidinfrom6
diﬀerent experiments using blood samples from 6 diﬀerent normal
volunteers.
3.6. The Eﬀect of Dermcidin on the Inhibition of Endothelial
Nitric Oxide Synthase (eNOS). As described in the results,
the injection of dermcidin that led to the increase of BPs
in the animal model was associated with the decrease of
the plasma NO level (Figure 2). Nitric oxide, demonstrated
to be the endothelial-derived vasorelaxing factor, has been
reported to be a global antihypertensive agent [13]. And,
as such, the dermcidin-induced reduction of plasma NO
level could be suggested to result in the increase of systemic
hypertension. However, eNOS by itself has been reported to
have little or no basal enzymic activity for the productionThrombosis 7
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Figure 5: Lineweaver-Burk plot of the inhibition of nitric oxide
synthase activated by insulin in the cell-free homogenate from
the goat artery endothelial cells. The cell-free homogenate of the
endothelial cells from the carotid artery of the goat was prepared
as described in Section 2. Lineweaver-Burk plot was constructed
by adding diﬀerent amounts of l-arginine to the reaction mixture
containing 100μunits/mL insulin in the presence or absence of
0.1μM dermcidin. The line A represents the formation of NO in
the presence of insulin, and the line B represents the formation of
NO in the presence of both the insulin and dermcidin. Each point
represents mean of 5 diﬀerent experiments each in triplicate.
of NO, and this enzyme in the endothelial cells has been
reported to be stimulated only in the presence of appropriate
activators for the synthesis of NO leading to the control of
the elevated BPs [13].
As only limited numbers of physiologic activators of
eNOS are known [13] and since insulin has been reported to
stimulate NO synthesis in various cells including endothelial
cells [11], the dermcidin-induced inhibition of the insulin
activated nitric oxide synthase leading to the inhibition
of NO production from l-arginine was determined by
adding dermcidin to the goat endothelial cell homogenate
preparation treated with insulin in the presence of l-arginine
(the substrate).
Lineweaver-Burk plot of the eNOS in the supernatant
from the endothelial cell homogenate in the presence of
insulinthatresultedinthestimulationofNOsynthesisinthe
reaction mixture as described in Section 2 demonstrated that
the Km of eNOS was 9.43μM arginine with the maximum
velocity(Vmax)of7nmolNO/h/mg.Theadditionof0.1μM
dermcidin to the reaction mixture increased the Km from
9.43μM to 26.3μM arginine with concomitant decrease of
the Vmax from 7nmol NO/h/mg to 3.8nmol NO/h/mg
indicating that the rate synthesis of NO in the presence
of insulin was decreased by nearly 50% in the presence of
0.1μM dermcidin in vitro (Figure 5).
3.7. The Eﬀect of Dermcidin on the Inhibition of Glucose-
Stimulated Release and Synthesis of Pancreatic Insulin. As
described above, dermcidin was a potent inhibitor of insulin
activated nitric oxide synthase and thereby might play a
criticalroleinthedevelopmentofhypertension.Studieswere
further conducted to determine its role in the pancreatic
synthesis of insulin. It was found that the addition of 0.02M
glucose to the incubation mixture containing the pancreatic
islets of Langerhans resulted in the increase of insulin
synthesis from the basal 0.012±0.004μunits insulin/mg/h to
0.088 ± 0.005μunits insulin/mg/h. In contrast, the addition
of 0.1μM dermcidin in the incubation mixture resulted in
the inhibition of the insulin synthesis by 50% (0.006μunits
insulin/mg/h) (P<0.0001; n = 5).
3.8. Eﬀect of Administration of Aspirin on the Plasma Derm-
cidin and Insulin Level in Patients with Acute Myocardial
Infarction (AMI). It has been described above that the use of
aspirin in vivo was capable of reducing the plasma dermcidin
level due to the systemic increase of NO level (Table 2). To
determine whether the ingestion of aspirin could have any
eﬀect on the plasma insulin level in AMI who had plasma
insulin level of 15μunits/dL (Median), all participating
subjects with the condition (n = 29) were asked to ingest
350mg of aspirin. It was found that the oral administration
of aspirin in AMI patients resulted in the increase of plasma
insulin level from 15μunits/dL (median; ranging from 25 to
0μunits/dL) before the ingestion of aspirin to 150μunits/dL
(median; ranging from 125 to 40μunits/dL) after the inges-
tion of the compound within 24h. It was also found that
therewasaconcomitantdecreaseinthedermcidinlevelfrom
116nM (median) (ranging from 72nM to 173nM) to 11nM
(median) ranging from 0nM to 45nM. The coeﬃcient of
correlation (r) between the plasma dermcidin and insulin
level was determined to be −0.70 (without aspirin) and
−0.721 (with aspirin) indicating that the plasma dermcidin
and insulin levels were negatively correlated.
4. Discussion
As described above, an oxidative stress protein, determined
to be dermcidin, was not only found to appear in the
circulation of the hypertensive subjects (Figure 1), but the
stress-induced protein of Mr 11kDa was also found to be a
potent inducer of platelet aggregation (Figure 4). Although
it was not possible for us to demonstrate directly the ef-
fects of dermcidin in the increase of blood pressures in
human subjects, the plasma dermcidin level in hypertensive
subjects was highly correlated with both the systolic (r =
+0.924) and diastolic (r = +0.909) blood pressure levels in
hypertensive subjects (Table 1). Furthermore, the injection
of the dermcidin itself in rabbits was found to acutely
increasethebloodpressurelevels.Theincreaseofbloodpres-
sure was found to be related to the decrease of plasma NO
level induced by the injection of dermcidin in the circulation
of the test animal. On the other hand, the decrease of the
plasmadermcidinlevelinhypertensivevolunteersbytheoral
administrationofaspirinwhichhasbeenreportedtoincrease
plasma NO level in humans [12, 16] resulted simultaneously
in the reduction of both the systolic and diastolic pressures8 Thrombosis
with concomitant decrease of plasma dermcidin level in
the hypertensive subjects (Table 2). The correlation coeﬃ-
cient “r” (Pearson value) between the reduction of plasma
dermcidin levels and the systolic and diastolic pressures was
+0.689 and +0.846 respectively indicating that the reduction
of these pressures was positively correlated to the reduction
of the plasma dermcidin level. Thus, not only the increase
of plasma dermcidin was highly correlated to the increase
of both diastolic and systolic pressures in the hypertensive
subjects but also the decrease of the plasma dermcidin level
was highly correlated to the decrease of the blood pressures
in these subjects. In separate experiments, it was found that
thedermcidin-induceddecreaseoftheplasmaNOlevelwasa
consequence of the inhibition of a constitutive form of nitric
oxidesynthase(cNOS)activatedbyinsulinintheendothelial
cells from the carotid artery from goat (Figure 5). Nitric
oxide, a global vasodilating agent [13], originally identiﬁed
as “endothelial derived relaxing factor” [13], is known to
be produced in the endothelial cells. However, contrary
to the expectation, the endothelial nitric oxide synthase
(eNOS) had no basal enzymic activity for the synthesis of
NO and appropriate stimulator was needed for the synthesis
of NO by the enzyme [13]. The numbers of physiologic
stimulators for the eNOS currently reported are however
limited. Only a kidney-cortex-derived hypotensive protein
called renal cortexin [25] and insulin [11] are currently
known to activate eNOS in the endothelial cells homogenate
in vitro.A sr e p o r t e di nSection 3, dermcidin was a potent
inhibitor of insulin-induced activated eNOS that led to
the inhibition of systemic NO synthesis in the endothelial
cells homogenate. Lineweaver Burk plot of the dermcidin-
induced eﬀect on the insulin-activated eNOS demonstrated
that dermcidin was a competitive inhibitor of the enzyme
and was found to compete with l-arginine, the substrate
of eNOS (Figure 5) for the synthesis of NO. Similar results
were also obtained using renal cortexin (0.1μM) in the
inhibition by dermcidin on the cortexin-activated eNOS of
theendothelialcellhomogenate(unpublished).Theseresults
suggested that dermcidin could act as systemic competitive
inhibitor of NOS of the endothelial cells.
As described above, the aggregation of human blood
platelets induced by dermcidin was induced by the activation
of the platelet cyclooxygenase.
Although the eﬀect of dermcidin in the increase of
blood pressures lasted only for 4h in the animal model,
as the stress-induced protein, on mol/mol basis, was found
t ob e4 0t i m e sm o r ee ﬀective activator of cyclooxygenase
when compared to that by ADP itself, dermcidin could be
critically important in the development of CAD through
thrombus in hypertension [12] even if the increase of plasma
dermcidin level was only for a short time. It should be
mentioned that the injection of dermcidin was capable of
developing coronary artery disease in the animal model in
the suboptimal amount of ADP within 30min [12].
The development of atherosclerosis has been established
to be the major pathological event leading to CAD [3]. Hy-
pertension and diabetes mellitus are reported to be the
two most important risk factors for atherosclerosis among
other risk factors including dyslipidemia, hyperhomocys-
teinemia, dysregulation of blood coagulation, and ﬁbrinol-
ysis [4]. However, the biochemical mechanism involved in
the hypertension-induced atherosclerosis remains obscure.
As described in the results, not only dermcidin increased
blood pressure and induced platelet aggregation leading to
CAD through thrombogenesis, but also it has been found
that the stress-induced protein was a potent inhibitor of
insulin synthesis in the pancreatic β cells [12]a sw e l l
as in the hepatocytes. In this context, dermcidin-induced
inhibition of insulin was unique in that no other protein is
currently known which is capable of inhibiting pancreatic
insulin synthesis. The hypertensive protein could potentially
be a double-edged risk factor for atherosclerosis leading to
CAD through the development of both hypertension and
diabetes mellitus. The inhibition of insulin-induced NO
synthesis in the endothelial cells (Figure 5) could result itself
in hypertension. Although the systemic decrease of NO level
would be expected to result in the increase of BPs [30], no
physiologicinhibitorofNOsynthesisinhumanshasyetbeen
reported that may initiate the increase of systemic BPs. In
this sense, dermcidin, a protein produced due to stress, was
unique in its role in the development of hypertension.
5. Conclusion
Close association between insulin resistance and hyperten-
sion has been reported before [30]. Our studies revealed a
relation between hypertension and diabetes mellitus leading
to the development of atherosclerosis. Dermcidin, which led
to the inhibition of pancreatic insulin synthesis as well as the
inhibition of insulin-induced NO synthesis, seems to oﬀer
a possible link between the two major risk factors leading
to atherosclerosis due to repeated exposure to stress, and
the stress-induced protein might actually precipitate CAD
through the activation of platelet cyclooxygenase leading to
platelet aggregation.
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